{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "by-licensee", "type": "clause", "offset": [30, 41]}, {"key": "licensee-inventions", "type": "definition", "offset": [49, 68]}, {"key": "commercialized-pozen-product", "type": "definition", "offset": [159, 187]}, {"key": "technology-will", "type": "clause", "offset": [290, 305]}, {"key": "to-the-extent", "type": "clause", "offset": [342, 355]}, {"key": "directed-to", "type": "definition", "offset": [356, 367]}, {"key": "gastroprotective-agent", "type": "definition", "offset": [370, 392]}, {"key": "chemical-agent", "type": "clause", "offset": [444, 458]}], "samples": [{"hash": "cFk0EucoGSV", "uri": "/contracts/cFk0EucoGSV#formulation-technology", "label": "Collaboration and License Agreement (Pozen Inc /Nc)", "score": 25.7227926078, "published": true}, {"hash": "3eTykk37SRc", "uri": "/contracts/3eTykk37SRc#formulation-technology", "label": "Collaboration and License Agreement (Pozen Inc /Nc)", "score": 25.7227926078, "published": true}, {"hash": "ije5mCCq5Ha", "uri": "/contracts/ije5mCCq5Ha#formulation-technology", "label": "Collaboration and License Agreement (Horizon Pharma, Inc.)", "score": 25.3887748118, "published": true}], "snippet": "means any Know-How Controlled by Licensee in the Licensee Inventions that are used by Licensee in the manufacture, use, sale or import of the formulation of a Commercialized POZEN Product, and any Patents Controlled by Licensee claiming such Licensee Inventions; provided, that Formulation Technology will not include any Patents or Know-How to the extent directed to a Gastroprotective Agent, non-steroidal anti-inflammatory, or other drug or chemical agent, or any methods of manufacture or use thereof.", "size": 5, "hash": "51ebff6fecbb99ae649dc1e8fa55df03", "id": 1}, {"snippet_links": [], "samples": [{"hash": "eWH5JjoMsus", "uri": "/contracts/eWH5JjoMsus#formulation-technology", "label": "License and Collaboration Agreement (Menlo Therapeutics, Inc.)", "score": 29.0465434634, "published": true}, {"hash": "dNMpYVvBdUT", "uri": "/contracts/dNMpYVvBdUT#formulation-technology", "label": "License and Collaboration Agreement (Menlo Therapeutics, Inc.)", "score": 28.9890485969, "published": true}, {"hash": "a2rdzhz32JX", "uri": "/contracts/a2rdzhz32JX#formulation-technology", "label": "License and Collaboration Agreement (Menlo Therapeutics, Inc.)", "score": 28.9260780287, "published": true}], "snippet": "has the meaning set forth in Section 2.9.", "size": 4, "hash": "03347167c73b208f044c30cd967d20d1", "id": 2}, {"snippet_links": [{"key": "patent-rights", "type": "definition", "offset": [29, 42]}, {"key": "related-to", "type": "clause", "offset": [56, 66]}, {"key": "the-process", "type": "clause", "offset": [72, 83]}, {"key": "program-compound", "type": "definition", "offset": [118, 134]}, {"key": "to-provide", "type": "definition", "offset": [144, 154]}, {"key": "for-example", "type": "clause", "offset": [209, 220]}], "samples": [{"hash": "2jFEaBrXjeM", "uri": "/contracts/2jFEaBrXjeM#formulation-technology", "label": "Research Collaboration and License Agreement (Mirati Therapeutics, Inc.)", "score": 24.5181382615, "published": true}, {"hash": "eh3iQHnVQhB", "uri": "/contracts/eh3iQHnVQhB#formulation-technology", "label": "Research Collaboration and License Agreement (Mirati Therapeutics, Inc.)", "score": 24.3538672142, "published": true}], "snippet": "Formulation Technology means Patent Rights and Know-How related to: (a) the process of adding chemical additives to a Program Compound in order to provide such Program Compound with pharmaceutical properties (for example, stability, solubility, pH, etc.) acceptable for administration to the eye in humans; and (b) the composition of such chemical additives alone or when combined with a Program Compound.", "size": 4, "hash": "ddd452df9c3d31f835f1b40061aa05ea", "id": 3}, {"snippet_links": [{"key": "drug-delivery-technology", "type": "definition", "offset": [46, 70]}, {"key": "delivery-of-a", "type": "clause", "offset": [128, 141]}, {"key": "characteristics-of", "type": "definition", "offset": [208, 226]}, {"key": "oral-formulation", "type": "definition", "offset": [230, 246]}], "samples": [{"hash": "l1s4q2stJyO", "uri": "/contracts/l1s4q2stJyO#formulation-technology", "label": "Exclusive License Agreement", "score": 23.9281314168, "published": true}, {"hash": "LrtwF7ufsv", "uri": "/contracts/LrtwF7ufsv#formulation-technology", "label": "Exclusive License Agreement", "score": 23.9281314168, "published": true}, {"hash": "aLpSoLpCslW", "uri": "/contracts/aLpSoLpCslW#formulation-technology", "label": "Exclusive License Agreement (Depomed Inc)", "score": 21.0, "published": true}], "snippet": "means Depomed\u2019s proprietary gastric retentive drug delivery technology currently known as AcuFormTM technology used to optimize delivery of a drug by achieving improved pharmacokinetic and/or pharmacodynamic characteristics of an oral formulation of such drug when compared to immediate release formulations of such drug.", "size": 3, "hash": "d8952d1f46c69787a6c74030d01107e8", "id": 4}, {"snippet_links": [{"key": "delivery-of", "type": "clause", "offset": [42, 53]}, {"key": "distribution-of", "type": "clause", "offset": [125, 140]}, {"key": "provided-that", "type": "clause", "offset": [223, 236]}, {"key": "modification-of", "type": "clause", "offset": [315, 330]}], "samples": [{"hash": "f1GO5Y88mUJ", "uri": "/contracts/f1GO5Y88mUJ#formulation-technology", "label": "Collaboration and License Agreement (Affymax Inc)", "score": 19.0, "published": true}, {"hash": "bevRemw6vF5", "uri": "/contracts/bevRemw6vF5#formulation-technology", "label": "Collaboration and License Agreement (Affymax Inc)", "score": 19.0, "published": true}], "snippet": "means any technology useful to facilitate delivery of therapeutic compounds, or that is useful to optimize the absorption or distribution of therapeutic compounds in the body, but that is not itself a therapeutic compound; provided that Formulation Technology shall exclude any technology that comprises a chemical modification of the Peptide, [*] or Hematide.", "size": 3, "hash": "fb7e575fdf6972169c02ec44689ecb61", "id": 5}, {"snippet_links": [{"key": "new-inventions", "type": "definition", "offset": [33, 47]}, {"key": "collaboration-compound", "type": "definition", "offset": [79, 101]}, {"key": "to-provide", "type": "definition", "offset": [112, 122]}, {"key": "for-clarity", "type": "clause", "offset": [422, 433]}, {"key": "all-purposes", "type": "definition", "offset": [476, 488]}, {"key": "active-pharmaceutical-ingredients", "type": "definition", "offset": [501, 534]}], "samples": [{"hash": "i8HfOlNMXSL", "uri": "/contracts/i8HfOlNMXSL#formulation-technology", "label": "Collaboration and License Agreement (NovaBay Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "85DTVnAO3be", "uri": "/contracts/85DTVnAO3be#formulation-technology", "label": "Collaboration and License Agreement (NovaBay Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet": "means technologies, materials or New Inventions used in the formulation of any Collaboration Compound hereunder to provide or to enhance properties thereof, including efficacy, durability, safety, ease of handling, compatibility, stability, bioavailability, solubility, delivery route or the like, together with any and all formulations comprising a Collaboration Compound with such technologies, materials or inventions. For clarity, Formulation Technology shall exclude for all purposes any and all active pharmaceutical ingredients themselves.", "size": 2, "hash": "7541e4c0a3cf1df549d17c8c24887f63", "id": 6}, {"snippet_links": [{"key": "other-technology", "type": "clause", "offset": [66, 82]}, {"key": "relating-to", "type": "definition", "offset": [83, 94]}, {"key": "active-pharmaceutical-ingredients", "type": "definition", "offset": [185, 218]}], "samples": [{"hash": "ggRgPaq5dev", "uri": "/contracts/ggRgPaq5dev#formulation-technology", "label": "License Agreement (Imprimis Pharmaceuticals, Inc.)", "score": 23.6639288159, "published": true}, {"hash": "5nx3uZqSfk5", "uri": "https://investors.harrowinc.com/static-files/1e464933-8ccd-437f-aea1-a4f9112bb88f", "label": "investors.harrowinc.com", "score": 10.0308008214, "published": false}], "snippet": "means all inventions, discoveries, data, information, samples and other technology relating to the formulation (including topical, oral and suspension formulations) and optimization of active pharmaceutical ingredients, excluding Contract Formulations.", "size": 2, "hash": "a2eb203cfc807df169135d376c011000", "id": 7}, {"snippet_links": [{"key": "by-licensee", "type": "clause", "offset": [30, 41]}, {"key": "licensee-inventions", "type": "definition", "offset": [49, 68]}, {"key": "commercialized-pozen-product", "type": "definition", "offset": [159, 187]}, {"key": "technology-will", "type": "clause", "offset": [290, 305]}, {"key": "to-the-extent", "type": "clause", "offset": [342, 355]}, {"key": "directed-to", "type": "definition", "offset": [356, 367]}, {"key": "gastroprotective-agent", "type": "definition", "offset": [370, 392]}, {"key": "chemical-agent", "type": "clause", "offset": [444, 458]}, {"key": "related-persons", "type": "definition", "offset": [710, 725]}, {"key": "for-purposes-of-section", "type": "clause", "offset": [756, 779]}, {"key": "securities-exchange-act-of-1934", "type": "clause", "offset": [793, 824]}, {"key": "as-amended", "type": "definition", "offset": [826, 836]}, {"key": "the-recitals", "type": "clause", "offset": [882, 894]}, {"key": "investigational-new-drug-application", "type": "clause", "offset": [916, 952]}, {"key": "the-fda", "type": "clause", "offset": [964, 971]}, {"key": "indirect-tax", "type": "clause", "offset": [1007, 1019]}, {"key": "value-added-taxes", "type": "clause", "offset": [1027, 1044]}, {"key": "sales-taxes", "type": "definition", "offset": [1046, 1057]}, {"key": "taxes-and-other", "type": "clause", "offset": [1071, 1086]}, {"key": "initial-pozen-product", "type": "definition", "offset": [1108, 1129]}, {"key": "subject-of", "type": "clause", "offset": [1238, 1248]}, {"key": "during-the-term", "type": "clause", "offset": [1340, 1355]}, {"key": "performance-of-activities", "type": "clause", "offset": [1363, 1388]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [1400, 1426]}, {"key": "by-employees", "type": "clause", "offset": [1427, 1439]}, {"key": "independent-contractors", "type": "definition", "offset": [1452, 1475]}, {"key": "either-party", "type": "definition", "offset": [1479, 1491]}, {"key": "such-party", "type": "clause", "offset": [1545, 1555]}, {"key": "joint-invention", "type": "clause", "offset": [1591, 1606]}, {"key": "of-licensee", "type": "clause", "offset": [1715, 1726]}, {"key": "joint-patent", "type": "definition", "offset": [1845, 1857]}, {"key": "joint-steering-committee", "type": "definition", "offset": [1957, 1981]}, {"key": "any-non", "type": "clause", "offset": [2006, 2013]}, {"key": "test-procedures", "type": "clause", "offset": [2260, 2275]}, {"key": "documents-and-files", "type": "clause", "offset": [2308, 2327]}, {"key": "the-foregoing", "type": "definition", "offset": [2338, 2351]}], "samples": [{"hash": "6lsq1xPYQ9m", "uri": "/contracts/6lsq1xPYQ9m#formulation-technology", "label": "Collaboration and License Agreement", "score": 31.340862423, "published": true}, {"hash": "7EPJVOfo7qL", "uri": "/contracts/7EPJVOfo7qL#formulation-technology", "label": "Collaboration and License Agreement (Horizon Pharma, Inc.)", "score": 25.1943874059, "published": true}], "snippet": "means any Know-How Controlled by Licensee in the Licensee Inventions that are used by Licensee in the manufacture, use, sale or import of the formulation of a Commercialized POZEN Product, and any Patents Controlled by Licensee claiming such Licensee Inventions; provided, that Formulation Technology will not include any Patents or Know-How to the extent directed to a Gastroprotective Agent, non-steroidal anti-inflammatory, or other drug or chemical agent, or any methods of manufacture or use thereof. 1.31 \u201cGastroprotective Agent\u201d means proton pump inhibitors and H2 receptor antagonists for the treatment, prevention or amelioration of injury to the gastrointestinal tract. 1.32 \u201cGroup\u201d means a group of related persons or entities deemed a \u201cperson\u201d for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. 1.33 \u201cHorizon\u201d has the meaning set forth in the recitals. 1.34 \u201cIND\u201d means an Investigational New Drug Application filed with the FDA pursuant to 21 CFR \u00a7 312.20. 1.35 \u201cIndirect Tax\u201d means value added taxes, sales taxes, consumption taxes and other similar taxes. 1.36 \u201cInitial POZEN Product\u201d means the POZEN Product containing non-enteric coated Esomeprazole and enteric-coated Naproxen that is the subject of NDA #22-511. 1.37 \u201cInvention\u201d means any invention, discovery or Know-How that is conceived during the Term in the performance of activities undertaken pursuant to this Agreement by employees, agents, or independent contractors of either Party, its Affiliates or Sublicensees and is Controlled by such Party, Affiliates or Sublicensees. 1.38 \u201cJoint Invention\u201d means any Invention that is conceived jointly by one or more employees, agents, or independent contractors of Licensee or its Affiliate(s) and one or more employees, agents, or independent contractors of POZEN or its Affiliate(s). 1.39 \u201cJoint Patent\u201d means a Patent claiming a Joint Invention. 1.40 \u201cJSC\u201d has the meaning set forth in Section 2.1.2 (Joint Steering Committee). 1.41 \u201cKnow-How\u201d means any non-public, documented or otherwise recorded or memorialized knowledge, experience, know-how, technology, information, and data, including formulas and formulations, processes, techniques, unpatented inventions, discoveries, ideas, and developments, test procedures, and results, together with all documents and files embodying the foregoing.", "size": 2, "hash": "7c3f1ab2c65ed89a3ca003cc7cbb567e", "id": 8}, {"snippet_links": [{"key": "by-licensee", "type": "clause", "offset": [30, 41]}, {"key": "licensee-inventions", "type": "definition", "offset": [49, 68]}, {"key": "commercialized-pozen-product", "type": "definition", "offset": [159, 187]}, {"key": "technology-will", "type": "clause", "offset": [290, 305]}, {"key": "to-the-extent", "type": "clause", "offset": [342, 355]}, {"key": "directed-to", "type": "definition", "offset": [356, 367]}, {"key": "gastroprotective-agent", "type": "definition", "offset": [370, 392]}, {"key": "chemical-agent", "type": "clause", "offset": [445, 459]}], "samples": [{"hash": "3Oaf1HegJFT", "uri": "http://ir.aralez.com/static-files/0aed33dc-6afe-4de8-8091-d3f82ca1257a", "label": "ir.aralez.com", "score": 8.1704312115, "published": false}], "snippet": "means any Know-How Controlled by Licensee in the Licensee Inventions that are used by Licensee in the manufacture, use, sale or import of the formulation of a Commercialized POZEN Product, and any Patents Controlled by Licensee claiming such Licensee Inventions; provided, that Formulation Technology will not include any Patents or Know-How to the extent directed to a Gastroprotective Agent, non- steroidal anti-inflammatory, or other drug or chemical agent, or any methods of manufacture or use thereof.", "size": 1, "hash": "588b1eda7ee7cb162863e22e570535ce", "id": 9}, {"snippet_links": [{"key": "delivery-of", "type": "clause", "offset": [54, 65]}, {"key": "conjugate-technology", "type": "definition", "offset": [191, 211]}, {"key": "an-example", "type": "clause", "offset": [215, 225]}], "samples": [{"hash": "hLei9pJAW9e", "uri": "/contracts/hLei9pJAW9e#formulation-technology", "label": "License Agreement (Isis Pharmaceuticals Inc)", "score": 26.5906913073, "published": true}], "snippet": "means technology designed to enhance the stability or delivery of an oligonucleotide where such technology is not an Oligonucleotide Modification. \u201cOligonucleotide Modification\u201d means [***]. Conjugate Technology is an example of an \u201cOligonucleotide Modification,\u201d but does not represent \u201cFormulation Technology.\u201d Lipid nanoparticle technology is an example of \u201cFormulation Technology.\u201d", "size": 1, "hash": "cc3c51f1ef5458500f6776b17cff4f43", "id": 10}], "next_curs": "CmMSXWoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj8LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIfZm9ybXVsYXRpb24tdGVjaG5vbG9neSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Formulation Technology", "snippet": "means any Know-How Controlled by Licensee in the Licensee Inventions that are used by Licensee in the manufacture, use, sale or import of the formulation of a Commercialized POZEN Product, and any Patents Controlled by Licensee claiming such Licensee Inventions; provided, that Formulation Technology will not include any Patents or Know-How to the extent directed to a Gastroprotective Agent, non-steroidal anti-inflammatory, or other drug or chemical agent, or any methods of manufacture or use thereof.", "size": 30, "id": "formulation-technology", "examples": ["How shall mean all Know-How that is included within Ipsen New <strong>Formulation Technology</strong>.", "For the avoidance of doubt, Ipsen retains all rights to and under the Ipsen <strong>Formulation Technology</strong> (i) in relation to any compounds, or products containing any compound, other than Licensed Compound, Licensed Product, PTH, PTHrP or analogs of PTH or PTHrP, and (ii) to perform \u2587\u2587\u2587\u2587\u2587\u2019\u2587 obligations under the Research Agreement.", "The commencement, strategies, termination, and settlement of any action or proceedings relating to the validity or suspected or actual Infringement of the Ipsen Compound Technology, Ipsen <strong>Formulation Technology</strong>, Joint Inventions or Joint Patent Rights, or any portion thereof shall be decided by Nuvios in consultation with Ipsen.", "Ipsen provides no guarantee of success that its research activities under such research agreement will be successful and will result in a Licensed Compound formulated with Ipsen <strong>Formulation Technology</strong> that is eligible for further development activities.", "Notwithstanding the foregoing exclusive license rights granted to Nuvios in this paragraph with respect to the Ipsen <strong>Formulation Technology</strong>, Nuvios shall not exercise any or all of such exclusive license rights with respect to any formulation for Licensed Compound and/or Licensed Product that is different from the current formulation therefore as of the Effective Date unless and until Nuvios and Ipsen enter into the Research Agreement.", "Each Party shall give prompt written notice to the other of any suspected or actual Infringement by a third party of all or any portion of the Ipsen Compound Technology, Ipsen <strong>Formulation Technology</strong>, Nuvios Patent Rights, Nuvios Know-How, Nuvios Inventions, Joint Inventions or Joint Patent Rights (the Infringed Rights) that comes to the attention of that Party during the Royalty Term with respect to any and all countries in the Territory.", "In the event Nuvios intends to develop a formulation of the Licensed Product with the Ipsen <strong>Formulation Technology</strong>, Nuvios and Ipsen shall agree and enter into a separate research agreement containing a research work program and budget under which Ipsen shall use reasonable commercial efforts to carry out research activities to provide Nuvios with a Licensed Product formulated with Ipsen <strong>Formulation Technology</strong>.", "During the Term, (i) Ipsen shall not, except pursuant to the Research Agreement, use all or any portion of the Ipsen <strong>Formulation Technology</strong> for research purposes related to, or in connection with, Licensed Compound and/or Licensed Product, and (ii) Ipsen shall not grant to any third party the right to use all or any portion of the Ipsen <strong>Formulation Technology</strong> for research purposes related to, or in connection with, Licensed Compound and/or Licensed Product.", "To the extent any <strong>Formulation Technology</strong> is not Controlled by the Developing Party and is instead Controlled by a Third Party, upon the request of the other Party, the Developing Party will cooperate and in good faith facilitate negotiations between such Third Party and the other Party to allow the other Party to use and exploit such <strong>Formulation Technology</strong> in a manner consistent with the rights of such other Party under this Agreement.", "To the extent any <strong>Formulation Technology</strong> is Controlled by the Developing Party, it will automatically be included in the licenses granted to the other Party under Sections 2.1 or 2.5, as applicable."], "related": [["collaboration-technology", "Collaboration Technology", "Collaboration Technology"], ["information-technology", "Information Technology", "Information Technology"], ["manufacturing-technology", "Manufacturing Technology", "Manufacturing Technology"], ["information-technology-it-system", "Information Technology (IT) System", "Information Technology (IT) System"], ["information-technology-systems", "Information Technology Systems", "Information Technology Systems"]], "related_snippets": [], "updated": "2025-07-06T21:58:41+00:00"}, "json": true, "cursor": ""}}